Related Experiment Video

Updated: May 13, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?

Jianfeng Guo1, James C Evans, Caitriona M O'Driscoll

  • 1Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland.

Trends in Molecular Medicine
|March 19, 2013
PubMed

Insights

RNA interference (RNAi) gene therapy offers a promising approach for prostate cancer treatment by targeting oncogenes. Effective delivery systems are crucial for RNAi therapeutics to combat metastatic disease and improve patient quality of life.

Area of Science:

  • Oncology
  • Gene Therapy
  • Biotechnology

Background:

  • Prostate cancer is a leading cancer in men, with current treatments often causing side effects and failing against metastatic forms.
  • Oncogenes driving prostate cancer growth and spread are identified as potential therapeutic targets.
  • Effective delivery of therapeutic agents is a significant challenge in cancer treatment.

Purpose of the Study:

  • To review the potential of RNA interference (RNAi) for targeting prostate cancer oncogenes.
  • To explore the use of non-viral, bioresponsive 'smart' delivery systems for RNAi therapeutics.
  • To discuss how these systems can be optimized for the tumor microenvironment.

Main Methods:

  • Literature review of RNA interference mechanisms and delivery systems.
  • Analysis of oncogenes implicated in prostate cancer progression.
  • Discussion of bioresponsive and 'smart' delivery strategies for RNAi.

Main Results:

  • RNAi demonstrates potential for targeting key oncogenes in prostate cancer.
  • Non-viral, bioresponsive delivery systems show promise for enhanced therapeutic efficacy.
  • Tailoring delivery systems to the tumor microenvironment is critical for success.

Conclusions:

  • RNAi-based gene therapy, coupled with advanced delivery systems, represents a promising avenue for treating prostate cancer, including metastatic disease.
  • Bioresponsive 'smart' delivery systems offer a strategy to overcome current limitations in RNAi therapy for prostate cancer.
  • Further research into these delivery systems could significantly improve treatment outcomes and patient quality of life.

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.